Expenditure on Heart Failure in the United States: The Medical Expenditure Panel Survey 2009-2018
- PMID: 35902161
- PMCID: PMC9680004
- DOI: 10.1016/j.jchf.2022.05.006
Expenditure on Heart Failure in the United States: The Medical Expenditure Panel Survey 2009-2018
Abstract
Background: With rising United States health care expenditure, estimating current spending for patients with heart failure (HF) informs the value of preventative health interventions.
Objectives: The purpose of this study was to estimate current health care expenditure growth for patients with HF in the United States.
Methods: The authors pooled MEPS (Medical Expenditure Panel Survey) data from 2009-2018 to calculate total HF-related expenditure across clinical settings in the United States. A 2-part model adjusted for demographics, comorbidities, and year was used to estimate annual mean and incremental expenditures associated with HF.
Results: In the United States, an average of $28,950 (2018 inflation-adjusted dollars) is spent per year for health care-related expenditure for individuals with HF compared with $5,727 for individuals without HF. After adjusting for demographics and comorbidities, a diagnosis of HF was associated with $3,594 in annual incremental expenditure compared with those without HF. HF-related expenditure increased from $26,864 annual per person in 2009-2010 to $32,955 in 2017-2018, representing a 23% rise over 10 years. In comparison, expenditure on myocardial infarction, type 2 diabetes mellitus, and cancer grew by 16%, 28%, and 16%, respectively. Most of the cost was related to hospitalization: $12,569 per year. Outpatient office-based care and prescription medications saw the greatest growth in cost over the period, 41% and 24%, respectively. Estimated incremental national expenditure for HF per year was $22.3 billion; total annual expenditure for adults with HF was $179.5 billion.
Conclusions: HF is a costly condition for which expenditure is growing faster than that of other chronic conditions.
Keywords: Medical Expenditure Panel Survey; health care economics; health expenditure; heart failure (HF).
Published by Elsevier Inc.
Conflict of interest statement
Funding Support and Author Disclosures Dr Fonarow has served as a consultant for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Janssen, Medtronic, Merck, and Novartis. Dr Ziaeian’s research is supported by AHA SDG 17SDG33630113 and the National Institutes of Health/National Center for Advancing Translational Science (NCATS) UCLA CTSI grant number KL2TR001882. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures



Comment in
-
Expenditure on Heart Failure in the United States: A Rising Tide Lifts All Boats.JACC Heart Fail. 2022 Aug;10(8):581-582. doi: 10.1016/j.jchf.2022.06.003. JACC Heart Fail. 2022. PMID: 35902162 No abstract available.
References
-
- Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020:E139–E596. - PubMed
-
- Ward C, Ewald E, Koenig K, Schluterman N. Prevalence and Health Care Expenditures Among Medicare Beneficiaries Aged 65 Years and Over with Heart Conditions. Centers for Medicare and Medicaid Services: Office of Enterprise Data & Analytics; 2017.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous